{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancer+Unresectable&page=5", "query": { "condition": "Non-small Cell Lung Cancer Unresectable", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 239, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancer+Unresectable&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-small+Cell+Lung+Cancer+Unresectable&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T08:21:32.311Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02432963", "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Bladder Carcinoma", "Colon Carcinoma", "Estrogen Receptor Negative", "Head and Neck Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "HER2/Neu Negative", "Melanoma", "Non-Small Cell Lung Carcinoma", "Pancreatic Carcinoma", "Progesterone Receptor Negative", "Rectal Carcinoma", "Renal Cell Carcinoma", "Soft Tissue Sarcoma", "Triple-Negative Breast Carcinoma", "TP53 Gene Mutation", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Modified Vaccinia Virus Ankara Vaccine Expressing p53", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2016-06-14", "completion_date": "2026-10-02", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02432963" }, { "nct_id": "NCT05166616", "title": "Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Triptolide Analog", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-03-07", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05166616" }, { "nct_id": "NCT00526890", "title": "Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "selenomethionine", "type": "DIETARY_SUPPLEMENT" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 16, "start_date": "2006-10", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2017-11-28", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00526890" }, { "nct_id": "NCT04513925", "title": "A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 829, "start_date": "2020-08-24", "completion_date": "2025-07-31", "has_results": true, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 25, "location_summary": "Palo Alto, California • Greeley, Colorado • Fort Myers, Florida + 21 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Greeley", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Palm Bay", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04513925" }, { "nct_id": "NCT03229278", "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Cancer", "Recurrent Bladder Carcinoma", "Recurrent Classical Hodgkin Lymphoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Renal Cell Carcinoma", "Stage III Bladder Cancer", "Stage III Lymphoma", "Stage III Non-Small Cell Lung Cancer AJCC v7", "Stage III Renal Cell Cancer", "Stage III Skin Melanoma", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIA Skin Melanoma", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Lymphoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Bladder Cancer", "Stage IVB Bladder Cancer", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Enzyme Inhibitor Therapy", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-10-03", "completion_date": "2022-10-30", "has_results": true, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03229278" }, { "nct_id": "NCT04866017", "title": "A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2021-06-17", "completion_date": "2023-10-17", "has_results": true, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 1, "location_summary": "Bolivar, Missouri", "locations": [ { "city": "Bolivar", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04866017" }, { "nct_id": "NCT06108479", "title": "Study of DF6215 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Solid Tumor Cancer" ], "interventions": [ { "name": "DF6215", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "KEYTRUDA®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2023-11-28", "completion_date": "2025-12-04", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 9, "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06108479" }, { "nct_id": "NCT03965689", "title": "Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Lung Non-Small Cell Squamous Carcinoma", "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Lung Non-Squamous Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2020-04-16", "completion_date": "2027-03-20", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 10, "location_summary": "Los Angeles, California • Newport Beach, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03965689" }, { "nct_id": "NCT06667908", "title": "A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "JNJ-90301900", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Concurrent Chemo/Radiation Therapy (cCRT)", "type": "RADIATION" }, { "name": "Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin", "type": "DRUG" }, { "name": "Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "Johnson & Johnson Enterprise Innovation Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2024-12-06", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 18, "location_summary": "La Jolla, California • Farmington, Connecticut • New Haven, Connecticut + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06667908" }, { "nct_id": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Anaplastic Thyroid Cancer", "Bone Metastases", "Carcinoma of the Appendix", "Distal Urethral Cancer", "Fallopian Tube Cancer", "Gastrinoma", "Glucagonoma", "Inflammatory Breast Cancer", "Insulinoma", "Liver Metastases", "Localized Unresectable Adult Primary Liver Cancer", "Lung Metastases", "Male Breast Cancer", "Malignant Pericardial Effusion", "Malignant Pleural Effusion", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Parathyroid Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Newly Diagnosed Carcinoma of Unknown Primary", "Occult Non-small Cell Lung Cancer", "Pancreatic Polypeptide Tumor", "Primary Peritoneal Cavity Cancer", "Proximal Urethral Cancer", "Pulmonary Carcinoid Tumor", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adrenocortical Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Carcinoma of Unknown Primary", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Parathyroid Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Thyroid Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Skin Metastases", "Small Intestine Adenocarcinoma", "Somatostatinoma", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Adrenocortical Carcinoma", "Stage III Bladder Cancer", "Stage III Cervical Cancer", "Stage III Colon Cancer", "Stage III Endometrial Carcinoma", "Stage III Esophageal Cancer", "Stage III Follicular Thyroid Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Pancreatic Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Prostate Cancer", "Stage III Rectal Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Anal Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Anal Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Adrenocortical Carcinoma", "Stage IV Anal Cancer", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Gastric Cancer", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Papillary Thyroid Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Urethral Cancer Associated With Invasive Bladder Cancer", "WDHA Syndrome" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "ABI-007/carboplatin/trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-10-07T08:21:32.311Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004074" } ] }